Table 2.
Week 24 | Week 48 | |
---|---|---|
Proportion with HIV-1 RNA <40 copies/mL – ITT | ||
Overall (N=21) | 15/21 (71%) | 14/21 (67%) |
Patients with baseline HIV viremia (N=15) | 11/15 (73%) | 10/15 (67%) |
Patients with baseline HIV-1 RNA <40copies/mL (N=6) | 4/6 (67%) | 4/6 (67%) |
Protocol-defined virologic failure | ||
Missing data | 3 (14%) | 2 (10%) |
Lost to follow-up | 2 (10%) | 2 (10%) |
Discontinued treatment for SAE/death | 0 | 1 (5%) |
Discontinued treatment for other reason | 0 | 1 (5%) |
HIV-1 RNA ≥40 copies/mL | 1 (5%) | 1 (5%) |
Abbreviations: ITT, intention-to-treat; TDF/FTC/EVG/cobi plus DRV, tenofovir disoproxil fumarate, emtricitabine, and cobicistat-boosted elvitegravir plus darunavir; SAE, serious adverse event.